Junshi Biosciences(SH:688180)2025-02-27 08:45Revenue and Sales Performance - Total revenue for 2024 reached RMB 194,831.73 million, an increase of 29.67% compared to RMB 150,254.99 million in the previous year[3] - The core product, Toripalimab, saw a significant sales increase of over 60% in the domestic market due to improved sales efficiency and additional approved indications[5] - The company has four commercialized drugs, including Toripalimab, Adalimumab, Dexamethasone, and Engorimab, contributing to revenue growth[5] Financial Performance - The company reported a net loss attributable to shareholders of RMB 128,227.92 million, an improvement from a loss of RMB 228,343.19 million in the previous year[3] - Total assets decreased by 4.95% from RMB 1,134,286.69 million at the beginning of the period to RMB 1,078,190.66 million at the end of the period[3] - The weighted average return on net assets improved to -19.73%, up by 7.59 percentage points from -27.32% in the previous year[3] Strategic Initiatives - The company is actively expanding its global commercialization network, with Toripalimab approved in multiple countries including the US, EU, and India[5] - The company is focusing on cost control and enhancing sales efficiency as part of its "Quality Improvement and Efficiency Enhancement" action plan[6] - The company is advancing its pipeline, including late-stage candidates and exploring new products for clinical trials[7] Product Development - New indications for Toripalimab have been approved, including treatments for triple-negative breast cancer and advanced renal cell carcinoma[6]